Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic

Ziad Bakouny; Marco Paciotti; Andrew L Schmidt; Stuart R Lipsitz; Toni K Choueiri; Quoc-Dien Trinh

doi:10.1001/jamaoncol.2020.7600

Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic

JAMA Oncol. 2021 Mar 1;7(3):458-460. doi: 10.1001/jamaoncol.2020.7600.

Authors

Ziad Bakouny¹, Marco Paciotti^{2

3

4}, Andrew L Schmidt¹, Stuart R Lipsitz³, Toni K Choueiri¹, Quoc-Dien Trinh^{2

3}

Affiliations

¹ Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Division of Urological Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
³ Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Department of Urology, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.

Abstract

This cohort study describes the number of patients undergoing cancer screening tests and of ensuing cancer diagnoses during the COVID-19 pandemic in 1 health care system in the northeastern United States.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
COVID-19*
Colonoscopy / statistics & numerical data
Early Detection of Cancer / trends*
Female
Humans
Male
Mammography / trends
Massachusetts / epidemiology
Middle Aged
Neoplasms / diagnosis*
Neoplasms / epidemiology
Papanicolaou Test / trends
Prostate-Specific Antigen / blood
SARS-CoV-2
Tomography, X-Ray Computed / trends

Substances

Prostate-Specific Antigen